中紅醫療(300981.SZ):科倫醫械部分產品擬中選集中帶量採購項目
格隆匯1月8日丨中紅醫療(300981.SZ)公佈,公司控股子公司江西科倫醫療器械製造有限公司(簡稱“科倫醫械”)於近期參加了滁州市部分醫用耗材聯動降價備案項目的投標工作。根據滁州市部分普通醫用耗材帶量聯動降價備案企業名單公吿顯示,科倫醫械部分產品擬中選上述集中帶量採購項目。
科倫醫械注射器2023年度銷售收入為7013.65萬元,佔科倫醫械2023年度營業收入的32.83%,佔公司2023年度營業收入的3.33%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.